---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056850"
form_type: "8-K"
ticker: "LITS"
cik: "0001262104"
company_name: "Lite Strategy, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:00:17.313224+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MEI Pharma reports Q3 FY2024 cash $56.6M, no revenue; prioritizes voruciclib program

## Summary
- Cash, equivalents & investments $56.6M at Mar 31, 2024; no revenue for Q3 vs $5.9M prior year.
- R&D expenses $5.2M (down from $15.1M YoY) due to zandelisib wind-down; G&A $4.6M (down from $7.2M).
- Voruciclib Phase 1 expansion cohort enrolling; complete responses observed in R/R AML patients.
- Board unanimously prioritizes voruciclib, decides against second return of capital under cooperation agreement.
- ME-344 formulation development initiated; update expected in first half of calendar 2025.

## SEC filing metadata
- accession: 0000950170-24-056850
- form_type: 8-K
- ticker: LITS
- cik: 0001262104
- company_name: Lite Strategy, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1262104/000095017024056850/0000950170-24-056850-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1262104/000095017024056850/meip-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056850
- JSON: https://secwatch.observer/filing/0000950170-24-056850.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056850.txt

## Key facts
- Earnings Releases
  Lite Strategy, Inc. reported financial results for third quarter ended March 31, 2024.
  - Period: third quarter ended March 31, 2024
  - Result: reported results
  source text: On May 9, 2024, MEI Pharma, Inc. (the “Company”) issued a press release announcing its financial results for its third quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1262104/000095017024056850/0000950170-24-056850-index.htm
- Earnings Releases
  Lite Strategy, Inc. reported three and nine months ended March 31, 2024 results: net income As of March 31, 2024, MEI had $56.6 million in cash, cash equivalents, and short-term investments with no outstanding de.
  - Period: three and nine months ended March 31, 2024
  - Net income: As of March 31, 2024, MEI had $56.6 million in cash, cash equivalents, and short-term investments with no outstanding de
  - Result: reported results
  source text: As of March 31, 2024, MEI had $56.6 million in cash, cash equivalents, and short-term investments with no outstanding debt.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1262104/000095017024056850/0000950170-24-056850-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.